Dermatology · El Paso, TX
Dermatology and skin studies in El Paso, TX
7 recruiting studies have a site in El Paso.
7 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- El Paso, TX + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- El Paso, TX + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- El Paso, TX + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 2
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Novartis Pharmaceuticals
- Location
- El Paso, TX
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- El Paso, TX + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- El Paso, TX + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- El Paso, TX + 65 other US sites
- Eligibility basics
- Ages 2–11
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.